MTOR and neoplasm: In this specific category of patients (high-grade ECs), an analysis of the whole tumor genomic profile becomes mandatory, as it has been highlighted that some of these patients show peculiar molecular alterations, mainly of the AKT/PI3K/mTOR pathways and the PIK3CA gene, which may open new therapeutic perspectives [38].